Zobrazeno 1 - 10
of 107
pro vyhledávání: '"YIQING DU"'
Autor:
Peiyong Guan, Jianfeng Chen, Chengqiang Mo, Tomoya Fukawa, Chao Zhang, Xiuyu Cai, Mei Li, Jing Han Hong, Jason Yongsheng Chan, Cedric Chuan Young Ng, Jing Yi Lee, Suet Far Wong, Wei Liu, Xian Zeng, Peili Wang, Rong Xiao, Vikneswari Rajasegaran, Swe Swe Myint, Abner Ming Sun Lim, Joe Poh Sheng Yeong, Puay Hoon Tan, Choon Kiat Ong, Tao Xu, Yiqing Du, Fan Bai, Xin Yao, Bin Tean Teh, Jing Tan
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 9, Pp 2132-2145 (2024)
Abstract Collecting duct carcinoma (CDC) is an aggressive rare subtype of kidney cancer with unmet clinical needs. Little is known about its underlying molecular alterations and etiology, primarily due to its rarity, and lack of preclinical models. T
Externí odkaz:
https://doaj.org/article/26e77e47357b4536980d9f63bd24fbcb
Publikováno v:
Pharmacological Research, Vol 211, Iss , Pp 107543- (2025)
Fibroblast growth factor receptor (FGFR) alteration is one of the common driver alterations in urothelial carcinoma (UC). FGFR alterations contribute to anti-tumor immunity inhibition and are associated with attenuated response to immune checkpoint i
Externí odkaz:
https://doaj.org/article/b5a85a6a632f4f9fb13410085212125a
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Bladder cancer (BCa) exhibits significant sex disparities, and intravesical Bacillus Calmette-Guerin (BCG) is a widely used treatment for non-muscle invasive bladder cancer (NMIBC). A comprehensive evaluation of intravesical BCG, including the safety
Externí odkaz:
https://doaj.org/article/f341dfcf209246199d3c8d89aaaad245
Publikováno v:
Advanced Science, Vol 11, Iss 40, Pp n/a-n/a (2024)
Abstract Chimeric Antigen Receptor (CAR) T‐cell therapy is a promising cancer treatment method. However, its application in bladder cancer (BC) remains limited, partially because of the absence of appropriate target molecules. Sialylated cancer‐d
Externí odkaz:
https://doaj.org/article/24edabe66e0349b1b38f1d84d0ff3046
Publikováno v:
Pharmacological Research, Vol 205, Iss , Pp 107230- (2024)
Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment. Fibroblast growth factor receptor (FGFR) alterations, as common oncogenic drivers in UC, have been reported to drive T cell depletion of UC immune microenviron
Externí odkaz:
https://doaj.org/article/01e03560a51b43e1bf8ecc78f249763c
Publikováno v:
BMC Anesthesiology, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Regional anesthesia appears to reduce cancer recurrence, but the optimal anesthesia modality for non-muscle invasive bladder cancer (NMIBC) were still under debate. Therefore, we sought to assess the effect of regional and GA only
Externí odkaz:
https://doaj.org/article/d4a1c78544364e5badbfd5d496e9e3b2
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractObjective The optimal cycle of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) remains controversial. This study aimed to compare the efficacy of three and four cycles of NAC in the treatment of MIBC through a systema
Externí odkaz:
https://doaj.org/article/b02b6832df324b8092dec6caf937fe72
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Immune checkpoint blockade (ICB) therapy holds promise in metastatic urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell-depleted microenvironment in UC, which led to the hypothesis that FGFR3 muta
Externí odkaz:
https://doaj.org/article/8ca303dd07ea450d8801b6e1ea970872
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Intratumoral fibrosis was positively correlated with histological grade of renal clear cell carcinoma (ccRCC) and intratumoral inflammation. However, the association of intratumoral fibrosis with the immune infiltration of ccRCC w
Externí odkaz:
https://doaj.org/article/7f62e478ae8b47a2afc3daf34dd8d374
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
RationaleTo invest the role of androgen deprivation therapy (ADT) on the tumor immune microenvironment of prostate cancer.MethodsHere we have profiled the transcriptomes of 19,227 single cells from 4 prostate tumors, including two cases who received
Externí odkaz:
https://doaj.org/article/6718d79294ab429babcbcca10c498900